Orphan Drugs Market Overview:

Global Orphan Drugs Market is expected to garner $169 billion from $106 billion and register a CAGR of 6.8% during the forecast period, 2016-2022. Orphan drug can be defined as a pharmaceutical agent specifically designed to treat rare (orphaned) diseases. These diseases differ from usual diseases as their prevalence rate is very low and hence appeal to a very small patient population. Therefore, as compared to non-orphan drugs, these drugs do not guarantee feasible returns on investment. However, various government authorities encourage to develop and market such drugs. Cost associated with the development of these drugs is higher when compared with non-orphan drugs. The different indications for which orphan drugs are used include lymphoma, leukemia, cystic fibrosis, and others.

Get more information on this report : Request Sample Pages

The demand for the orphan drugs has increased significantly owing to surge in prevalence of rare diseases. In addition, the rise in awareness among the populace regarding rare diseases, increase in R&D investment, and drug development drive the market growth.

The orphan drugs market is segmented based on disease type, indication, and geography. Based on disease type, the industry is divided into oncologic diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases. In the disease type segment, oncologic diseases occupied dominant share in 2015. In addition, it is expected to maintain the trend during the forecast period. This is due to the array of different forms of rare cancers, such as leukemia, myeloma, angiosarcoma, and others prevalent in the patient population.

Drivers, Restraints, and opportunities

The impact of the driving factors is expected to overcome the effect of restraints. Moreover, growth in novel indications for known orphan drugs and untapped emerging economies are expected to provide new market opportunities to orphan drug manufacturers in the near future.

Global Orphan Drugs Market: Key Product Segment

North America accounted for the largest market share in the orphan drugs market in 2015, and is expected to retain its dominance throughout the forecast period.

The key players operating in the global orphan drug market include AbbVie Inc., Aegerion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Pfizer Inc. and Sanofi.

Other prominent players in the value chain include Bayer HealthCare Pharmaceuticals Inc., Vertex Pharmaceuticals, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Amgen Inc., Biogen Idec, Actelion Pharmaceuticals Ltd, AstraZeneca plc, and Janssen Biotech, Inc.

Orphan Drugs Market Report Key Benefits:

It provides an in-depth analysis with current trends and future estimations to elucidate the imminent investment pockets

It offers a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities

It includes profiles of key market players and their strategies, which helps in understanding competitive outlook of the market

It consists of Porters Five Forces model to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players

Orphan Drugs Market Key Segments:

By Disease Type

Oncologic Diseases

Metabolic Diseases

Hematologic and Immunologic Diseases

Infectious Diseases

Neurologic Diseases

Other Rare Diseases

By Indication

Non-Hodgkin Lymphoma

Acute Myeloid Leukemia

Cystic Fibrosis

Glioma

Pancreatic Cancer

Ovarian Cancer

Multiple Myeloma

Duchenne Muscular Dystrophy

Graft vs Host Disease

Renal Cell Carcinoma

Others

By Geography